| Ann Arbor Staging; N (%) |
| |
Stage I |
9 (64) |
| |
Stage II |
3 (21) |
| |
Stage III |
0 (0) |
| |
Stage IV |
2 (14) |
| Histology |
| |
NK-T cell lymphoma |
1 (7) |
| |
Diffuse large B-cell lymphoma |
1 (7) |
| |
Large B-cell lymphoma |
1 (7) |
| |
Large cell lymphoma;burkitts |
1 (7) |
| |
Low grade lymphoma; atypical lymphoma cells |
1 (7) |
| |
MALT |
3 (21) |
| |
Diffuse large B cell lymphoma |
4 (29) |
| |
Follicular lymphoma |
1 (7) |
| |
Nodular sclerosis; HD |
1 (7) |
| Chemotherapy regimen; N (%) |
| |
ABVD |
1 (7) |
| |
CHOP |
1 (7) |
| |
R-CHOP |
5 (36) |
| |
R-CDOP |
1 (7) |
| |
Rituxan |
2 (14) |
| |
None |
4 (29) |
| Radiation technique; N (%) |
| |
IFRT |
12 (86) |
| |
3D-CRT |
1 (7) |
| |
None |
1 (7) |
| Total radiation dose in Gy; N (%) |
| |
2000 |
1 (7) |
| |
2975 |
1 (7) |
| |
3000 |
1 (7) |
| |
3600 |
7 (50) |
| |
4000 |
1 (7) |
| |
4500 |
1 (7) |
| |
6000 |
1 (7) |
| |
None |
1 (7) |
| NK: natural killer cell; MALT: mucosa associated lymphoid tissue; HD: Hodgkin’s disease; A:Adriamycin; B: belomycin; V:vinblastine; D:dacarbazine; R: rituximab; C:cyclophosphamide; O:vincristine; IFRT: involved field radiation therapy; 3D-CRT:3 dimensional conformal radiation therapy;Gy: gray |
